Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSLN.L Regulatory News (SLN)

  • There is currently no data for SLN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Publication in Cardiovascular Research

15 Apr 2021 07:00

RNS Number : 5154V
Silence Therapeutics PLC
15 April 2021
 

 

Silence Therapeutics Announces Publication in Cardiovascular Research Highlighting the Emerging Potential of RNA Therapeutics in Preventing Lipoprotein(a)-Mediated Cardiovascular Disease

- High Lipoprotein(a) is a genetically determined cardiovascular risk factor affecting around 20% of the world's population

 

15 April 2021

 

LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq: SLN ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced a new review publication on the prevention of cardiovascular disease linked to high lipoprotein(a) - Lp(a) - levels in the latest issue of Cardiovascular Research, linked here.

 

The paper, authored by senior medical and scientific experts from both Silence and leading cardiology centers, explores the emerging potential of RNA interference (RNAi) therapeutics in lowering elevated levels of Lp(a), which are associated with higher cardiovascular risk compared to the general population. Published in the European Society of Cardiology's research journal, the paper provides a timely assessment of current approaches to managing high Lp(a), which is estimated to affect around 20% of the world's population or a staggering 1.4 billion people globally.

 

Giles Campion, MD, EVP, Head of R&D and Chief Medical Officer of Silence Therapeutics said: "There is a growing body of evidence demonstrating high Lp(a) as a key predeterminant of cardiovascular disease, including premature heart attack and stroke. Unlike high cholesterol, which is a modifiable risk factor, high Lp(a) is a genetic risk factor that you cannot manage through diet or lifestyle changes. When considering a potential long-term preventative treatment for a large population, Lp(a)-lowering therapy must be safe, effective, well tolerated and conveniently administered. Our review explores the promising potential of RNAi therapies to fit that profile and address a major unmet need in cardiovascular disease."

 

Silence is evaluating its wholly owned lead RNAi candidate, SLN360, for the treatment of high Lp(a) levels in the ongoing global APOLLO Phase 1 trial. In pre-clinical studies to date, SLN360 has demonstrated sustained and deep reduction of Lp(a) serum levels (>90%) with an excellent safety profile. The Company anticipates reporting data in the single-ascending dose portion of the study in the second half of 2021. More information on the study can be found here.

 

 

 

 

 

 

Enquiries:

 

Silence Therapeutics plc

Gem Hopkins, Head of IR and Corporate Communications

ir@silence-therapeutics.com

 

 

Tel: +1 (646) 637-3208

Investec Bank plc (Nominated Adviser and Broker)

Daniel Adams/Gary Clarence

 

Tel: +44 (0) 20 7597 5970

European PR

Consilium Strategic Communications

Mary-Jane Elliott/ Angela Gray / Chris Welsh

silencetherapeutics@consilium-comms.com

 

Tel: +44 (0) 20 3709 5700

 

About SLN360

Silence's wholly owned lead product candidate, SLN360, is a gene 'silencing' therapy - one that is designed to temporarily block a specific gene's message that would otherwise trigger an unwanted effect. In this case, it aims to 'silence' LPA, a gene that tells the body to make a specific protein that is only found in Lp(a). By silencing the LPA gene, the levels of Lp(a) are lowered, which in turn is expected to lower the risk of heart diseases, heart attacks and strokes.

 

About Lipoprotein(a) 

Lipoprotein(a), known as Lp(a) for short, is a particle made by the liver, which consists of cholesterol, fats and proteins. Most people have some Lp(a) in their body, but about 1 in 5 people have high levels of Lp(a), because of a specific gene variation in their DNA. Most people are unaware if they have elevated Lp(a). People living with elevated Lp(a) have a higher risk of developing early heart disease, heart attacks and strokes. Most standard cholesterol tests do not currently include screening for Lp(a). Current medicines that are used to lower other lipid levels in the blood do not have a meaningful effect on Lp(a) and are less effective overall in people with high levels of Lp(a).

 

About Silence Therapeutics

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical need. Silence's proprietary mRNAi GOLD™ platform can be used to create siRNAs that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence's wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a) and SLN124 designed to address iron loading anemias. Silence also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals, and Takeda, among others. For more information, please visit https://www.silence-therapeutics.com/.

 

Forward-Looking Statements

Certain statements made in this announcement are forward-looking statements, including with respect to the Company's clinical development timeline and commercial prospects. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements, including the potential impact of COVID-19 on the Company's clinical development and regulatory timelines and plans. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RESEAELLFEXFEAA
Date   Source Headline
22nd Oct 200712:49 pmPRNHolding(s) in Company
9th Oct 200710:58 amPRNIssue of Equity
2nd Oct 20071:30 pmPRNDirector/PDMR Shareholding
28th Sep 20077:00 amPRNHalf-yearly Report
26th Sep 200711:28 amPRNHolding(s) in Company
10th Sep 20077:00 amPRNResearch Update
6th Sep 20077:05 amPRNNotice of Results
4th Sep 20077:30 amPRNHolding(s) in Company
24th Aug 20074:10 pmPRNHolding(s) in Company
23rd Aug 200712:45 pmPRNHolding(s) in Company
20th Aug 20071:08 pmPRNHolding(s) in Company
16th Aug 200710:12 amPRNHolding(s) in Company
15th Aug 20073:25 pmPRNAIM Rule 26
15th Aug 20072:52 pmPRNHolding(s) in Company
9th Aug 20072:18 pmPRNHolding(s) in Company
9th Aug 20077:01 amRNSHolding(s) in Company
2nd Aug 20073:53 pmPRNHolding(s) in Company
2nd Aug 200710:55 amPRNResult of AGM
31st Jul 200710:27 amPRNTotal Voting Rights
31st Jul 20077:00 amPRNRe Agreement
27th Jul 20077:00 amPRNDirectorate Change
27th Jul 20077:00 amPRNDirectorate Change
20th Jul 200711:35 amPRNHolding(s) in Company
13th Jul 20074:09 pmPRNHolding(s) in Company
11th Jul 20073:37 pmPRNHolding(s) in Company
10th Jul 200712:56 pmPRNHolding(s) in Company
9th Jul 20072:27 pmPRNNotice of AGM
9th Jul 200711:01 amPRNHolding(s) in Company
6th Jul 20074:51 pmPRNIssue of Equity
6th Jul 20071:00 pmPRNRe Agreement
2nd Jul 20074:06 pmPRNIssue of Equity
29th Jun 20077:00 amPRNAnnual Report and Accounts
26th Jun 200711:33 amPRNTotal Voting Rights
21st Jun 20073:28 pmPRNHolding(s) in Company
20th Jun 20071:55 pmPRNCorrection : Holding(s) in Company
15th Jun 20077:00 amRNSConference Attendance
14th Jun 20077:00 amPRNIssue of Equity
13th Jun 20073:20 pmPRNHolding(s) in Company
6th Jun 200711:15 amPRNHolding(s) in Company
30th May 20077:05 amPRNHolding(s) in Company
29th May 20074:20 pmPRNHolding(s) in Company
29th May 200710:44 amPRNHolding(s) in Company
21st May 20073:37 pmPRNIssue of Equity
11th May 20074:26 pmPRNHolding(s) in Company
9th May 200711:45 amPRNIssue of Equity
4th May 20077:01 amRNSSR Pharma Name Change
30th Apr 20071:50 pmPRNTotal Voting Rights
26th Apr 200710:30 amPRNEGM Statement & Research Update
23rd Apr 20077:05 amPRNIssue of Equity
3rd Apr 20079:45 amPRNDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.